

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

**SUPPLEMENTAL ANNOUNCEMENT TO
THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025**

Reference is made to the annual report of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2025 (the “**Annual Report**”). Terms used herein shall have the same meanings as defined in the Annual Report unless otherwise stated.

Further to the information disclosed in the Annual Report, the board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to provide shareholders of the Company and the potential investors with the following supplementary information on the section titled “Management Discussion and Analysis” of the Annual Report:

Likely timeframe, if the development is successful, for the Core Product to reach commercialisation

The Group’s Core Product is EAL[®]. As of 31 December 2025, the Group expected EAL[®] to reach commercialisation by December 2026, should the development of EAL[®] be successful.

References are made to (a) the announcements published by the Company dated 28 April 2026 and 3 June 2026 respectively; and (b) the section titled “Business Review – R&D of the product candidates – non-genetically modified cell product pipeline – EAL[®]” of the interim report of the Company for the six months ended 30 June 2026 (the “**Interim Report**”), in relation to the status of the Group’s new drug application for EAL[®]. The Group has been communicating with the CDE in relation to the protocol for the confirmatory clinical trial. It has submitted the draft protocol to the CDE in early June 2026, and has been required to commence the confirmatory clinical trial upon finalisation of the protocol. Based on information then available to the Group and previous experience, the Company expected to commence confirmatory trial within the first quarter of 2027, and resubmit the new drug application for EAL[®] for the prevention of postsurgical recurrence of liver cancer within approximately 39 months thereafter. Accordingly, the Group expected EAL[®] to reach commercialisation within 12 months after its submission of a new drug application for EAL[®] to the CDE, should the development of EAL[®] be successful.

The Company emphasises that its expectation to resubmit such new drug application for EAL[®] within approximately 39 months upon commencement of the confirmatory clinical trial, was based on previous experience and information then known to the Company. The actual duration of the confirmatory clinical trial may differ from such expectation due to factors including (among others) CDE’s regulatory policies and requirements, the nature of EAL[®], and the actual progress of such confirmatory clinical trial.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that the Group will be able to obtain further approval for, or ultimately market, EAL[®], successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 30 September 2026

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Mr Yang Fan, Mr Wang Ruihua, Mr Wang Donghu, Mr Yang Xin, Mr Liu Rui and Mr Cao Ran as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit, Ms Peng Sujiu and Mr Zhang Guoguang as independent non-executive Directors.